<DOC>
	<DOCNO>NCT00004779</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess safety efficacy gene transfer nasal epithelium use Ad5-CB-CFTR , E1-deleted adenovirus vector contain cystic fibrosis transmembrane conductance regulator gene , patient cystic fibrosis ( CF ) . II . Determine whether ion transport abnormality CF airway cell correct .</brief_summary>
	<brief_title>Phase I Pilot Study Ad5-CB-CFTR , Adenovirus Vector Containing Cystic Fibrosis Transmembrane Conductance Regulator Gene , Patients With Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Groups 3 patient receive 1 4 dos Ad5-CB-CFTR , recombinant E1-deleted adenovirus serotype 5 vector contain cystic fibrosis transmembrane conductance regulator gene . Ad5-CB-CFTR administer 1 nasal cavity vehicle alone administer opposite nasal cavity control .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Cystic fibrosis No mild genetic mutation , i.e. , normal nasal chloride ion permeability At least 2 week since decrease pulmonary function Prior/Concurrent Therapy At least 3 month since systemic cortisone At least 1 month since therapeutic research study , e.g. , DNAse Patient Characteristics Other : Adequate endocrine , liver , kidney , cardiac function Adenovirus antibody seropositive No pregnant nursing woman Negative pregnancy test require fertile woman Adequate contraception require fertile patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>